Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Bio-Techne Corporation

TECH

HIGHLY FAVORABLE

June 1, 2026

Research Conclusion

At ~$65 (May 2026 estimated), Bio-Techne offers outstanding quality-value setup: 75% probability-weighted upside with 16:1 bull/bear asymmetry (bear case -8%). Synthesized fair value $95-$135 (mid $115). The thesis combines (a) destocking recovery confirmed Q1 FY25 with +8% EPS YoY inflection, (b) 74% gross margin + 40% EBITDA margin = best-in-class life sciences tools economics, (c) multiple at structural trough 8-9x EV/EBITDA vs. peer 15-22x and TECH historical 18-35x, (d) deleveraging $1.0B → $0.4B over 5y plus modest buyback. Recommended stance: Strong Buy for quality-value portfolios. The Q2-Q3 FY25 confirmation of operating recovery is the binary catalyst; multi-method valuation converges $95-140 vs current $65.

Company Overview & Moat Assessment

Bio-Techne Corporation (NASDAQ: TECH) is a Minneapolis-based life sciences tools company providing proteins, antibodies, immunoassays, and instruments to academic and biopharma research customers. Two segments: Protein Sciences (~75% of revenue) — R&D Systems antibodies, Wes/Ella protein analysis instruments, GMP proteins for cell therapy — and Diagnostics & Genomics (~25%) — RNAscope, Exosome diagnostics, Asuragen genomic assays. FY2024 revenue $1.10B; FY2025E ~$1.13B; gross margin 74%; adj EBITDA margin 40%; adj EPS $4.86 FY25E. June fiscal year. Net debt ~$1.0B (2.2x EBITDA). 51M diluted shares; modest buyback. Dividend $0.32/yr (0.5% yield). CEO Kim Kelderman. Q1 FY25 showed clear destocking recovery (+8% EPS YoY, first acceleration in over a year).

▲ Bull Case

  • ◆Protein Sciences accelerates to +9% organic: Instrument placements (Wes/Ella/Maurice) drive consumable pull-through; GMP protein for cell therapy scales.
  • ◆Margin reaches 43% by FY28: Operating leverage + mix shift; multiple expands to 16x.
  • ◆Spatial biology RNAscope clinical adoption: D&G growth +12-15% if FDA companion diagnostic achieved.

▼ Bear Case

  • ◆NIH budget cut 5%+: ~10% of revenue exposure; direct headwind.
  • ◆10x Genomics wins spatial biology: D&G growth stalls at 1-2%.
  • ◆Multiple stays at 9x: Quality trap; no re-rating without sustained beat-and-raise.
Primary Debate on Wall Street

“The Street debate is 'Is Q1 FY25 inflection durable?' Bull frame: destocking ending + GMP protein scale + multiple at structural trough = 75%+ upside. Bear frame: 10x competition + NIH risk + slow margin recovery = multiple stays compressed. Sell-side range $70-$130.”

Top Catalysts
  • ◆Q2 FY25 earnings — recovery confirmation
  • ◆Q3 FY25 earnings — sustained inflection
  • ◆GMP protein order momentum — cell therapy ramp
  • ◆RNAscope clinical milestones — companion diagnostic
  • ◆FY26 guidance — multi-year recovery
  • ◆Multiple expansion — first re-rate above 11x
  • ◆NIH budget visibility — uncertainty removal
Top Risks
  • ◆Recovery stalls — primary thesis risk
  • ◆NIH budget cuts
  • ◆10x Genomics competition
  • ◆China deterioration
  • ◆Multiple stays compressed
  • ◆Major M&A (could be positive or negative)

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/TECH/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.